Shannon Soqui
Director/Board Member chez ACKL SPAC
Profil
Shannon Soqui is the founder of Next Frontier Brands.
He is currently the Chief Executive Officer & Director at Hempyre Holdings Ltd., the Non-Executive Vice Chairman at ACKRELL SPAC Partners I Co., the Executive Chairman at Next Frontier Pharmaceuticals, Inc., and the President & Secretary at CMLM Holdings, Inc. Previously, he worked as the Head-Cannabis Investment Banking at Ackrell Capital LLC from 2015 to 2017.
Mr. Soqui completed his undergraduate studies at the University of California and his graduate studies at The Santa Clara University School of Law.
Postes actifs de Shannon Soqui
| Sociétés | Poste | Début |
|---|---|---|
| ACKL SPAC | Director/Board Member | 01/12/2020 |
CMLM Holdings, Inc.
 CMLM Holdings, Inc. Specialty StoresRetail Trade CMLM Holdings, Inc. provides hemp-formulated wellness and beauty products. The company is headquartered in Portland, OR. | President | - |
Hempyre Holdings Ltd.
 Hempyre Holdings Ltd. Specialty StoresRetail Trade Hempyre Holdings Ltd. engages in the distribution of hemp-formulated consumer packaged goods for beauty, beverage, and wellness industries. The firm focuses on consumer hemp-formulated topical solutions to protect and rejuvenate the skin and body. Its product brands include QIND, Bio-Synergy, Muhu, QINDNESS, ActiVeman, Active Woman, Super7, Bottomley Distillers, Green Origin, Paways, and Wevapers. The company was founded on February 13, 2020 and is headquartered in London, the United Kingdom. | Chief Executive Officer | - |
Next Frontier Brands
 Next Frontier Brands Food DistributorsDistribution Services Next Frontier Brands engages in the provision of consumer goods. It offers beverage and hemp-based wellness brands. The company is headquartered in Boulder, CO. | Founder | - |
Next Frontier Pharmaceuticals, Inc.
 Next Frontier Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Next Frontier Pharmaceuticals, Inc. is a drug developer and provider of cannabinoid and psychedelic APIs. The private company is based in Carrollton, TX. Its wholly owned subsidiary, Benuvia Manufacturing, Inc., owns the FDA-approved cannabinoid drug Syndros® and the largest captive synthetic cannabinoid manufacturing facility. The company's 83,000 square foot manufacturing facility is permitted by the U.S. DEA to manufacture and export Schedule I to III controlled substances and is FDA registered. Next Frontier Pharmaceuticals is pursuing a 505(b)(2) approval pathway with the FDA for six investigational new drugs (INDs). The company also has a robust portfolio of patents and patents pending on organic and synthetic cannabinoids and provides life cycle management services for drug development companies focused on cannabinoids and psychedelics. | Chairman | - |
Anciens postes connus de Shannon Soqui
| Sociétés | Poste | Fin |
|---|---|---|
Ackrell Capital LLC
 Ackrell Capital LLC Investment ManagersFinance Ackrell Capital LLC operates as an independent investment bank that focuses on providing financial advisory services. It offers M&A advisory, private placement and corporate development services. The company was founded by Michael Kevin Ackrell and William A. Lamkin in 2003 and is headquartered in San Francisco, CA. | Corporate Officer/Principal | 01/01/2017 |
Formation de Shannon Soqui
| University of California | Undergraduate Degree |
| The Santa Clara University School of Law | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 6 |
|---|---|
Ackrell Capital LLC
Ackrell Capital LLC Investment ManagersFinance Ackrell Capital LLC operates as an independent investment bank that focuses on providing financial advisory services. It offers M&A advisory, private placement and corporate development services. The company was founded by Michael Kevin Ackrell and William A. Lamkin in 2003 and is headquartered in San Francisco, CA. | Finance |
CMLM Holdings, Inc.
CMLM Holdings, Inc. Specialty StoresRetail Trade CMLM Holdings, Inc. provides hemp-formulated wellness and beauty products. The company is headquartered in Portland, OR. | Retail Trade |
Hempyre Holdings Ltd.
Hempyre Holdings Ltd. Specialty StoresRetail Trade Hempyre Holdings Ltd. engages in the distribution of hemp-formulated consumer packaged goods for beauty, beverage, and wellness industries. The firm focuses on consumer hemp-formulated topical solutions to protect and rejuvenate the skin and body. Its product brands include QIND, Bio-Synergy, Muhu, QINDNESS, ActiVeman, Active Woman, Super7, Bottomley Distillers, Green Origin, Paways, and Wevapers. The company was founded on February 13, 2020 and is headquartered in London, the United Kingdom. | Retail Trade |
Ackrell SPAC Partners I Co.
 Ackrell SPAC Partners I Co. Financial ConglomeratesFinance Ackrell SPAC Partners I Co. is a blank check company. It plans to identify and to complete initial business combination in alcoholic and non-alcoholic beverage and wellness sectors of the fast-moving consumer goods market. The company was founded on September 11, 2018 and is headquartered in Claymont, DE. | Finance |
Next Frontier Brands
Next Frontier Brands Food DistributorsDistribution Services Next Frontier Brands engages in the provision of consumer goods. It offers beverage and hemp-based wellness brands. The company is headquartered in Boulder, CO. | Distribution Services |
Next Frontier Pharmaceuticals, Inc.
Next Frontier Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Next Frontier Pharmaceuticals, Inc. is a drug developer and provider of cannabinoid and psychedelic APIs. The private company is based in Carrollton, TX. Its wholly owned subsidiary, Benuvia Manufacturing, Inc., owns the FDA-approved cannabinoid drug Syndros® and the largest captive synthetic cannabinoid manufacturing facility. The company's 83,000 square foot manufacturing facility is permitted by the U.S. DEA to manufacture and export Schedule I to III controlled substances and is FDA registered. Next Frontier Pharmaceuticals is pursuing a 505(b)(2) approval pathway with the FDA for six investigational new drugs (INDs). The company also has a robust portfolio of patents and patents pending on organic and synthetic cannabinoids and provides life cycle management services for drug development companies focused on cannabinoids and psychedelics. | Health Technology |
